Skip to main content
An official website of the United States government

Dr. Asif Rizwan is a Program Director in the Diagnostic Biomarkers and Technology Branch (DBTB) of DCTD, where he leads efforts to develop biomarkers, innovative technologies and devices. These advancements aim to provide better research tools and assist clinical decision-making. His work integrates machine learning with cancer biology to advance diagnostics, prognostics, and prediction, transforming research into actionable tools to improve patient outcomes.

Dr. Rizwan joined NCI in February 2024, following his role as a Program Director at NHLBI, where he managed research grants in genomics, proteomics, and metabolomics. He contributed to initiatives such as TOPMed, BioData Catalyst, and trans-NIH RADx and HEAL, promoting AI/ML applications and cloud-based ecosystems. At NHLBI, he co-led NIEHS-NHLBI collaborations on projects linking health, environmental, and exposure data to address climate change’s health impacts.

Before joining NIH, Dr. Rizwan served as a Senior Scientific Officer at the DoD’s Congressionally Directed Medical Research Programs, overseeing a cancer research portfolio focused on biomedical engineering and data science. As a Research Fellow at Johns Hopkins Medicine, he conducted studies on cancer imaging, metastasis, and metabolism.

Dr. Rizwan earned his Ph.D. in Biophysics and Systems Biology from Cornell University. He has received NIH Director’s Awards (2021, 2022, 2023), authored numerous peer-reviewed publications, led trans-agency workshops, and driven impactful biomedical innovations. His expertise spans biomedical engineering, AI/ML, and omics, reflecting a career devoted to advancing health science and technology.

Selected Publications

Education

  • Ph.D., Cornell University and Memorial Sloan Kettering Cancer Center, NY 
  • M.S., University of Texas, Arlington, TX
  • Updated:
Email